随着蛋白质组学技术的快速发展和在疾病研究中的广泛应用,肿瘤标志物的发现研究又多了一个快速、灵敏和高通量的技术平台。但由于临床研究样本的个体变异、材料的高度复杂性、潜在标志蛋白的低丰度等因素的影响,肿瘤标志物的蛋白质组学研究尚面临许多困难和挑战。如何克服上述困难而有效利用蛋白质组学手段发现更多、更灵敏、更可靠的肿瘤标志物,为肿瘤的临床诊治提供更加强有力的支持是临床蛋白质组学研究的重要任务。 With the rapid development of proteomics technology and its wide application in disease research, a rapid, sensitive and high-throughput technology platform has been added to the discovery of tumor markers. However, due to the individual variations in clinical samples, the high complexity of materials, and the low abundance of potential marker proteins, the proteomics of tumor markers still faces many difficulties and challenges. How to overcome these difficulties and effectively use proteomics to find more, more sensitive, more reliable tumor markers, provide more powerful support for the clinical diagnosis and treatment of tumors is an important task of clinical proteomics research.